Zoll Medical AED Plus
This article was originally published in The Gray Sheet
Executive Summary
Automated external defibrillator shipments are expected to begin this summer following 510(k) clearance, announced March 26. Zoll's first offering for the public access defibrillator market, the device incorporates Rectilinear Biphasic waveform technology and also is the first AED to feature a single electrode pad and run on off-the-shelf batteries, according to Zoll. A patent infringement suit filed by competitor Cardiac Science March 28 in California federal court relates to Cardiac Science's '919 and '299 patents for electrode packaging and sensor technology, and seeks an injunction on sales and unspecified damages. Zoll says it is "confident that the AED Plus does not infringe these patents"...
You may also be interested in...
Zoll Seeks To Move Blood, AED Market With New CPR Device
Future automated external defibrillator market growth will be augmented by complementary technology developed to aid in other aspects of cardiopulmonary resuscitation, Zoll Medical President and CEO Richard Packer believes
Cardiac Science v. Zoll Medical
Settlement of patent infringement lawsuit includes cross-licensing of a number of patents related to automated public access defibrillators. In addition, Cardiac Science will receive an undisclosed initial licensing fee and ongoing royalties. The lawsuit involved Cardiac Science's '919 and '299 patents for electrode packaging and sensor technology and was filed March 28 in California federal court 1("The Gray Sheet" April 1, 2002, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”